Listen
DECTOVA (zanamivir)
Influenza
Opinions on drugs -
Posted on
Apr 24 2020
Reason for request
First assessment
Unfavourable opinion for reimbursement in the treatment of influenza (for more details, see MA).
Clinical Benefit
| Insufficient |
The clinical benefit of DECTOVA (zanamivir IV) is insufficient in the MA indication to justify its funding by the French national health insurance system.
|
Documents
English version
Contact Us
Évaluation des médicaments
